You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Computerized Alcohol Misuse Intervention with Micro-targeted Normative Feedback
SBC: RESEARCH CIRCLE ASSOCIATES Topic: NIAAADESCRIPTION (provided by applicant): Alcohol misuse continues to be a major public health problem in the United States, contributing substantially to morbidity, mortality, and social costs. There is a solid body of evidence supporting screening and brief intervention (SBI) for alcohol misuse on both public health and cost-effectiveness grounds, and the practice is endorsed by the U.S. Preventive H ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Use of Bispecific Antibody for Treating Non-obese Diabetes
SBC: TOLEROGENICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Activation of mature T lymphocytes is a multi-step process requiring both Ag-specific triggering of the TCR complex and co-stimulation mediated through the CD28-CD80/CD86 pathway. CTLA-4 is a critical inhibitor of T cell activation as evidenced by the lethal lympho-proliferation seen in CTLA-4 knockout mice. These signaling pathways play a primary role in T cel ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
A nanoparticle-based vaccine against leishmaniasis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): We propose to develop a recombinant subunit vaccine against cutaneous leishmaniasis. This vaccine will incorporate two protein antigens, TSA/TryP and P-4. Both antigens are highly conserved among Leishmania species, arerecognized by T cells of human patients, and confer protection against a live challenge in murine model studies. We expect that immunization usi ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Integrated molecular diagnostic system for the point-of-care
SBC: BIOHELIX CORPORATION Topic: NIAIDDESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic vents to gate fluid movements through micro channels, and multiple reaction chambers for experimenta ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Chronic wounds that fail to respond to traditional therapeutic interventions afflict millions of people each year, and direct costs associated with treating these wounds are estimated at 5 to 10 billion annually. Eradication of pathogenic bacteria that have colonized chronic wounds is complicated by the propensity of these bacteria to form ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Isolation of functional IgGs in the cytoplasm of a novel E. coli expression host
SBC: NEW ENGLAND BIOLABS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) hold great promise in human health with applications ranging from therapeutic agents that target cancer cells, to diagnostic biomarkers that can detect trace levels of a given antigen. Thispromise is best reflected in global sales of antibodies which reached nearly 31 billion in 2007 and future sales predicted to reach 56 billion ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
T cell cytokine assay for the diagnosis of disseminated Lyme borreliosis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with more than 28,000 cases reported annually. The infectioncan remain localized to the skin or disseminate to cause disease in the skin, heart, joints and nervous system. The ospC genotype of the spiroch ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies
SBC: Chrysalis BioTherapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Up to 30% of the US population are now affected by nasal allergy, resulting in a total (direct and indirect) cost of approximately 14.6 billion per year. Seasonal allergic rhinitis (AR), due to exposure to airborne pollen and molds is a major component of this problem in the US and worldwide. The limitations of current pharmaceutical and specific immunotherapy ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Use of milatuzumab in modulating graft vs. host disease
SBC: IMMUNOMEDICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Depletion of DCs has been demonstrated to be an effective approach for control of GVHD. We recently found that milatuzumab ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Covalent Vaccine for HIV
SBC: COVALENT BIOSCIENCE INCORPORATED Topic: NIAIDDESCRIPTION (provided by applicant): We propose a Phase I STTR study to develop a novel human immunodeficiency virus (HIV) vaccine strategy with the potential of world-wide efficacy. The HIV/AIDS pandemic remains a major global burden. No test vaccine based on traditional scientific principles has induced sufficiently protective immunity to HIV. Induction of neutralizing antibodies (Abs), the corn ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health